Evaluation of optimum timing for intravitreal injection of aflibercept for age-related macular degeneratio
Not Applicable
- Conditions
- Wet age-related macular degeneration
- Registration Number
- JPRN-UMIN000014946
- Lead Sponsor
- Faculty of life sciences, Kumamoto university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Presence of other causes of CNV, including pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye. Active intraocular inflammation in the study eye. Active ocular or periocular infection in study eye. Uncontrolled glaucoma in the study eye. Prior treatment with anti VEGF therapy in the study eye. History of myocardial infarction or stroke in the past 3 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of eyes at week 52 that maintained best-corrected visual acuity (BCVA; lost <15 letters from baseline); change from baseline in BCVA.
- Secondary Outcome Measures
Name Time Method